Puma Biotechnology (PBYI) to Release Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.24 per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Puma Biotechnology Price Performance

Shares of Puma Biotechnology stock opened at $6.68 on Thursday. The company has a market cap of $336.61 million, a PE ratio of 9.03 and a beta of 1.22. The firm has a fifty day moving average price of $6.31 and a two-hundred day moving average price of $5.43. Puma Biotechnology has a fifty-two week low of $2.58 and a fifty-two week high of $7.28.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PBYI. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Puma Biotechnology in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Insiders Place Their Bets

In other Puma Biotechnology news, insider Douglas M. Hunt sold 5,014 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $29,482.32. Following the sale, the insider directly owned 155,907 shares of the company’s stock, valued at approximately $916,733.16. This represents a 3.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Alan H. Auerbach sold 18,012 shares of Puma Biotechnology stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $105,910.56. Following the completion of the transaction, the chief executive officer owned 7,145,951 shares of the company’s stock, valued at $42,018,191.88. This trade represents a 0.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 43,937 shares of company stock valued at $257,513. Company insiders own 23.30% of the company’s stock.

Hedge Funds Weigh In On Puma Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of PBYI. Cerity Partners LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at $36,000. BNP Paribas Financial Markets increased its position in Puma Biotechnology by 39.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 2,290 shares in the last quarter. Abel Hall LLC acquired a new stake in Puma Biotechnology in the 4th quarter valued at about $64,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Puma Biotechnology in the first quarter worth about $66,000. Finally, Ieq Capital LLC acquired a new position in shares of Puma Biotechnology during the fourth quarter worth approximately $68,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.